Holen Sie sich die Stockscreener-App
1.23
6.82%
-0.09
Handel nachbörslich:
1.29
0.06
+4.88%
Schlusskurs vom Vortag:
$1.32
Offen:
$1.28
24-Stunden-Volumen:
268.86K
Relative Volume:
1.05
Marktkapitalisierung:
$21.50M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-8.89%
1M Leistung:
-64.14%
6M Leistung:
-61.56%
1J Leistung:
-72.85%
1-Tages-Spanne:
$1.23
$1.30
1-Wochen-Bereich:
$1.11
$1.37
52-Wochen-Spanne:
$1.11
$4.9588
Mural Oncology Plc Stock (MURA) Company Profile
Firmenname
Mural Oncology Plc
Sektor
Branche
Telefon
353 1 905 8020
Adresse
10 EARLSFORT TERRACE, DUBLIN 2
Vergleichen Sie MURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
1.23 | 21.50M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-25 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-25 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-06-28 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-04-04 | Eingeleitet | Morgan Stanley | Overweight |
Mural Oncology Plc Aktie (MURA) Neueste Nachrichten
40,025 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Virtu Financial LLC - Defense World
HC Wainwright Comments on Mural Oncology Q1 Earnings - Defense World
Mural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future Prospects - Seeking Alpha
HC Wainwright Lowers Mural Oncology (NASDAQ:MURA) Price Target to $6.00 - Defense World
Petri Dish: Late-stage cancer trial halt; Dyne names CFO - The Business Journals
Mural Oncology stock target cut to $6 at H.C. Wainwright By Investing.com - Investing.com UK
Mural Oncology downgraded to Hold from Buy at JonesResearch - TipRanks
Raymond James downgrades Mural Oncology after ovarian cancer failure - TipRanks
Mural Oncology (NASDAQ:MURA) Downgraded by Raymond James to Outperform - Defense World
Mural Oncology (NASDAQ:MURA) Given Hold Rating at Jones Trading - Defense World
Raymond James cuts Mural Oncology stock rating, slashes target to $6 - Investing.com UK
Morgan Stanley cuts Mural Oncology stock rating to Equal-weight By Investing.com - Investing.com UK
Mural Oncology downgraded to Equal Weight from Overweight at Morgan Stanley - TipRanks
Mural Oncology halts ovarian cancer drug development By Investing.com - Investing.com South Africa
Mural Oncology’s Phase III ovarian cancer trial failure knocks stock by 57% - Yahoo
Mural Oncology sinks on nemvaleukin miss in ovarian cancer - BioWorld MedTech
Mural Oncology halts ovarian cancer trial By Investing.com - Investing.com South Africa
Mural Oncology's Ovarian Cancer Combo Drug Trial Disappoints, Stock Plunges - Benzinga
Mural Oncology stock plunges on trial halt (MURA:NASDAQ) - Seeking Alpha
Jones Trading cuts Mural Oncology stock rating to hold By Investing.com - Investing.com UK
Mural Oncology halts ovarian cancer trial - Investing.com India
Mural Oncology halts ovarian cancer drug development - Investing.com India
Mural Oncology to Stop Development of Nemvaleukin for Ovarian Cancer; Shares Sink Pre-Bell - MarketScreener
Mural Oncology Provides Update on Phase 3 ARTISTRY-7 Trial of Nemvaleukin in Combination with KEYTRUDA® (pembrolizumab) in Patients with Platinum-Resistant Ovarian Cancer - The Manila Times
Clinical Trial Setback: Mural's Cancer Drug Falls Short in Phase 3 Ovarian Cancer Study - Stock Titan
Acquisition Of MSC Lung Cancer Screening Test Sends Shares Of This Micro Cap Higher - The Globe and Mail
Mural Oncology (MURA) Expected to Announce Earnings on Tuesday - Defense World
Q1 EPS Estimates for Mural Oncology Reduced by HC Wainwright - Defense World
HC Wainwright Reiterates Buy Rating for Mural Oncology (NASDAQ:MURA) - Defense World
Mural Oncology enters agreement for share sales By Investing.com - Investing.com South Africa
Mural Oncology enters agreement for share sales - Investing.com
Mural Oncology Announces Fourth Quarter and Year End 2024 Financial Results and Highlights Upcoming Clinical Milestones - The Manila Times
Mural Oncology Slashes Losses by 42% as Two Major Cancer Trial Results Approach - StockTitan
Mural Oncology CEO Caroline Loew sells shares worth $14,491 - Investing.com
Mural oncology officer sells shares worth $9,308 - Investing.com India
Mural oncology officer sells shares worth $9,308 By Investing.com - Investing.com South Africa
Mural Oncology's chief medical officer sells $51,293 in shares - Investing.com India
Mural Oncology’s chief medical officer sells $51,293 in shares - Investing.com
Exclusive: Mural Oncology Unveils Next-Gen Cancer Treatment Strategy at Major Healthcare Conference - StockTitan
Mural Oncology to Present at the TD Cowen 45th Annual Health Care Conference - The Manila Times
Mural Oncology plc (NASDAQ:MURA) Short Interest Update - MarketBeat
Alkermes plc (ALKS) reports earnings - Quartz
We Think Mural Oncology (NASDAQ:MURA) Needs To Drive Business Growth Carefully - Yahoo Finance
Mural Oncology (NASDAQ:MURA) Trading 8.8% HigherHere's What Happened - MarketBeat
Mural Oncology (NASDAQ:MURA) Trading 8.8% Higher – Here’s Why - Defense World
Jones Trading sets $16 target on Mural Oncology stock By Investing.com - Investing.com Nigeria
This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Geode Capital Management LLC Purchases 4,731 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts - The Manila Times
Mural Oncology Expands Pipeline with Two Novel Cancer Therapies, Advances Key Clinical Trials - StockTitan
Mural Oncology's chief legal officer sells $8,354 in shares By Investing.com - Investing.com Australia
Finanzdaten der Mural Oncology Plc-Aktie (MURA)
Es liegen keine Finanzdaten für Mural Oncology Plc (MURA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Mural Oncology Plc-Aktie (MURA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Keson-Brookes Maiken | See Remarks |
Mar 05 '25 |
Sale |
3.45 |
1,469 |
5,068 |
73,564 |
| Keson-Brookes Maiken | See Remarks |
Mar 04 '25 |
Sale |
3.36 |
1,262 |
4,240 |
75,033 |
| Loew Caroline | Chief Executive Officer |
Mar 04 '25 |
Sale |
3.36 |
4,313 |
14,492 |
305,590 |
1.23%
1.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):